N/A
N=40
Ablation Targets of Scar-related Ventricular Tachycardia Identified by Dynamic Functional Substrate Mapping
Tachycardia, Ventricular
Bottom Line
View on ClinicalTrials.gov: NCT05086510 ↗Enrolled (actual)
40
Serious AEs
15.0%
Results posted
Feb 2024
Primary outcome: Primary: Number of Participants With Recurrence of Ventricular Tachycardia — 13; 13 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Radiofrequency ablation (Procedure)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Ain Shams University
- Primary completion
- Jun 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Recurrence of Ventricular Tachycardia |
13; 13 | — |
| SECONDARY Number of Participants Who Experience Cardiac Death |
5; 4 | — |
| SECONDARY Number of Participants Who Die From Any Cause (All-cause Mortality) |
5; 4 | — |
Summary
This study aims at comparing the recurrence rates of ventricular tachycardia ablated after being mapped by 2 different techniques.
Eligibility Criteria
Inclusion Criteria
- • Patients with structural heart disease; previous myocardial infarction, left ventricular dilatation/systolic dysfunction, or normal left ventricular diameters/ systolic function with evidence of ventricular scar on contrast enhanced-cardiac magnetic resonance or electroanatomic map.
- Sustained monomorphic ventricular tachycardia documented by 12-lead ECG or implantable cardioverter defibrillator (electrograms resistant to antiarrhythmic drug treatment or requiring implantable cardioverter defibrillator therapies.
Exclusion Criteria
- • Patients with ventricular arrhythmias attributed to reversible causes.
Data sourced from ClinicalTrials.gov (NCT05086510). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.